Medgenics Reports First Quarter Financial Results

WAYNE, Pa. and MISGAV, Israel, May 8, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three months ended March 31, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company’s Quarterly Report on Form 10-Q.

This entry was posted in Recent Development News: Q2 - 2014. Bookmark the permalink.